A Network & Dyad HIV Prevention Intervention for IDU’s – 1

Overview

The purpose of this study is to evaluate a peer-based HIV prevention intervention that targets active injection drug users and their drug and sex partners.

Full Title of Study: “A Network & Dyad HIV Prevention Intervention for IDU’s”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: May 2008

Detailed Description

HIV seroincidence among injection drug users remains high, with unprotected sexual contact substantially contributing to new HIV infections among injection drug users (IDUs). Interventions that are culturally competent and target drug users' main sex and drug partners may be especially effective for HIV/STI and HCV control and prevention. The intervention to be tested in this study draws upon theoretical and empirical evidence suggesting that peer educator programs can have significant effects on the risk-related behaviors of both the educators and the peers whom they educate. Specifically, through group and individual focused sessions, participants learn and practice skills designed to reduce drug and sex related risk behaviors. Furthermore, individuals and their main risk partners attend a training session that focuses on risk reduction within their relationship.

Interventions

  • Behavioral: Intervention Condition
    • In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
  • Behavioral: Control Condition
    • The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.

Arms, Groups and Cohorts

  • Experimental: Intervention Condition
    • Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
  • Active Comparator: Control Condition
    • The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.

Clinical Trial Outcome Measures

Primary Measures

  • Any Sex Risk
    • Time Frame: 6 months
  • Talked About HIV-related Topics With Drug Buddies (in the Past Month)
    • Time Frame: 6 months
  • Showed a Needleless Syringe to Drug Buddies
    • Time Frame: 6 months
  • Talked About Responding to Overdose to Drug Buddies
    • Time Frame: 6 months
  • Any Injection Risk (Monthly Versus Never)
    • Time Frame: 12 months
  • Number of Needle or Cooker Sharers (2 or More Versus None)
    • Time Frame: 12 months
  • Talked About HIV-related Topics With Drug Buddies (in the Past Month)
    • Time Frame: 12 months
  • Showed a Needleless Syringe to Drug Buddies
    • Time Frame: 12 months
  • Any Injection Risk (Monthly Versus Never)
    • Time Frame: 18 months
  • Shared Cooker When Preparing Drugs
    • Time Frame: 18 months
  • Number of Needle or Cooker Sharers (2 or More Versus None)
    • Time Frame: 18 months
  • Injecting Drugs
    • Time Frame: 18 months
  • Talked About HIV-related Topics With Drug Buddies (in Past Month)
    • Time Frame: 18 months
  • Showed a Needleless Syringe to Drug Buddies
    • Time Frame: 18 months
  • Talked About Hepatitis to Drug Buddies
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

(i)Self reported injection drug use within the prior 6 months; (ii)Willingness to invite a risk network member into the study and to talk about HIV prevention; (iii)Age 18 or older Exclusion Criteria:

  • Not concurrently enrolled in another HIV prevention intervention

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Johns Hopkins Bloomberg School of Public Health
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Carl Latkin, Professor – Johns Hopkins Bloomberg School of Public Health
  • Overall Official(s)
    • Carl Latkin, Ph.D., Principal Investigator, Johns Hopkins University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.